Chromatin BioScience

Chromatin Bioscience designs synthetic promoters and gene expression control systems for cell and gene therapy developers.

Its platform uses bioinformatics to identify cell-type-selective regulatory elements from the human genome, which are assembled into novel synthetic promoters enabling precise, durable and targeted transgene expression.

The company's promoters are integrated into partner programmes across oncology, nephrology and rare disease gene therapies, with a clinical-stage collaboration supporting an in vivo CAR-T candidate for multiple myeloma.